ZVRA · Zevra Therapeutics Inc. Common Stock
View on chartInsiders & Stakes
| McFarlane Neil F. President and CEO | ▼ Sell | Open Market | 387,225 Shares held | 2/9/2026 | View profile |
| Clifton R. LaDuane CFO, Secretary & Treasurer | ▼ Sell | Tax Withholding | 143,515 Shares held | 12/31/2025 | View profile |
| John B. Bode Director | ▲ Buy | Option Exercise | 123,400 Shares held | 3/24/2026 | View profile |
| Schafer Joshua CCO & EVP, Bus. Development | ▼ Sell | Open Market | 62,278 Shares held | 2/3/2026 | View profile |
| Thompson Rahsaan Chief Legal & Compliance | ▼ Sell | Open Market | 37,569 Shares held | 8/14/2026 | View profile |
| Pascoe Richard W Executive Chairman | ▲ Buy | Open Market | 29,973 Shares held | 3/9/2023 | View profile |
| Sangiovanni Timothy J. SVP, Corporate Controller | ▼ Sell | Open Market | 29,590 Shares held | 2/3/2026 | View profile |
| Shih Alvin Director | ▲ Buy | Open Market | 20,000 Shares held | 9/12/2025 | View profile |
| Anderson Thomas Director | ▲ Buy | Open Market | 20,000 Shares held | 7/16/2024 | View profile |
| Plooster Matthew R Director | ▲ Buy | Open Market | 18,500 Shares held | 3/9/2023 | View profile |
| Mickle Travis C President & CEO | ▲ Buy | Open Market | 11,034 Shares held | 5/25/2022 | View profile |
| Tierney David S Director | ▲ Buy | Open Market | 10,835 Shares held | 3/9/2023 | View profile |
| Quartel Adrian W Chief Medical Officer | ▼ Sell | Open Market | 9,723 Shares held | 1/30/2026 | View profile |
| SEYMOUR TAMARA A Director | ▲ Buy | Open Market | 3,894 Shares held | 9/12/2025 | View profile |
| Watton Corey Michael Director | ▼ Sell | Open Market | 1,800 Shares held | 8/10/2026 | View profile |
Transaction History
| Thompson Rahsaan | ▼ Sell | Open Market | 42,666 | $475K | 8/14/2026 |
| Watton Corey Michael | ▼ Sell | Open Market | 12,300 | $138K | 8/10/2026 |
| Watton Corey Michael | ▲ Buy | Option Exercise | 12,300 | $61K | 8/10/2026 |
| Thompson Rahsaan | ▼ Sell | Open Market | 34,557 | $438K | 6/22/2026 |
| Thompson Rahsaan | ▲ Buy | Option Exercise | 66,667 | — | 6/21/2026 |
| Thompson Rahsaan | ▼ Sell | Open Market | 1,794 | $20K | 5/11/2026 |
| John B. Bode | ▲ Buy | Option Exercise | 39,200 | $195K | 3/24/2026 |
| John B. Bode | ▲ Buy | Option Exercise | 39,200 | $192K | 3/24/2026 |
| McFarlane Neil F. | ▼ Sell | Open Market | 14,625 | $125K | 2/9/2026 |
| McFarlane Neil F. | ▲ Buy | Option Exercise | 37,500 | — | 2/7/2026 |
| Sangiovanni Timothy J. | ▼ Sell | Open Market | 3,000 | $28K | 2/3/2026 |
| Schafer Joshua | ▼ Sell | Open Market | 10,500 | $97K | 2/3/2026 |
| McFarlane Neil F. | ▼ Sell | Open Market | 91,000 | $853K | 2/2/2026 |
| Schafer Joshua | ▲ Buy | Option Exercise | 35,334 | — | 1/31/2026 |
| McFarlane Neil F. | ▲ Buy | Option Exercise | 233,334 | — | 1/31/2026 |
| Sangiovanni Timothy J. | ▲ Buy | Option Exercise | 11,666 | — | 1/31/2026 |
| Schafer Joshua | ▼ Sell | Open Market | 3,375 | $30K | 1/30/2026 |
| Sangiovanni Timothy J. | ▲ Buy | Option Exercise | 6,333 | — | 1/30/2026 |
| Sangiovanni Timothy J. | ▼ Sell | Open Market | 1,750 | $15K | 1/30/2026 |
| Thompson Rahsaan | ▲ Buy | Option Exercise | 11,333 | — | 1/30/2026 |
| Thompson Rahsaan | ▼ Sell | Open Market | 4,080 | $36K | 1/30/2026 |
| Quartel Adrian W | ▲ Buy | Option Exercise | 11,333 | — | 1/30/2026 |
| Quartel Adrian W | ▼ Sell | Open Market | 4,533 | $40K | 1/30/2026 |
| Schafer Joshua | ▲ Buy | Option Exercise | 11,333 | — | 1/30/2026 |
| Clifton R. LaDuane | ▲ Buy | Option Exercise | 140,667 | $0 | 12/31/2025 |
| Clifton R. LaDuane | ▼ Sell | Tax Withholding | 48,513 | $435K | 12/31/2025 |
| McFarlane Neil F. | ▲ Buy | Option Exercise | 50,000 | — | 10/10/2025 |
| McFarlane Neil F. | ▼ Sell | Open Market | 19,500 | $211K | 10/10/2025 |
| SEYMOUR TAMARA A | ▲ Buy | Open Market | 3,175 | $25K | 9/12/2025 |
| Shih Alvin | ▲ Buy | Open Market | 20,000 | $158K | 9/12/2025 |
| John B. Bode | ▲ Buy | Open Market | 5,000 | $46K | 8/19/2025 |
| Thompson Rahsaan | ▼ Sell | Open Market | 24,000 | $221K | 6/26/2025 |
| Thompson Rahsaan | ▲ Buy | Option Exercise | 66,666 | — | 6/21/2025 |
| Watton Corey Michael | ▲ Buy | Open Market | 300 | $2K | 3/28/2025 |
| John B. Bode | ▲ Buy | Open Market | 10,000 | $80K | 3/19/2025 |
| McFarlane Neil F. | ▼ Sell | Open Market | 30,544 | $246K | 2/14/2025 |
| Sangiovanni Timothy J. | ▼ Sell | Open Market | 3,000 | $24K | 2/13/2025 |
| Schafer Joshua | ▼ Sell | Open Market | 10,500 | $83K | 2/13/2025 |
| Clifton R. LaDuane | ▼ Sell | Open Market | 11,000 | $86K | 2/13/2025 |
| McFarlane Neil F. | ▼ Sell | Open Market | 61,273 | $481K | 2/13/2025 |
| Schafer Joshua | ▲ Buy | Option Exercise | 35,333 | — | 1/31/2025 |
| Clifton R. LaDuane | ▲ Buy | Option Exercise | 43,333 | — | 1/31/2025 |
| McFarlane Neil F. | ▲ Buy | Option Exercise | 233,333 | — | 1/31/2025 |
| Sangiovanni Timothy J. | ▲ Buy | Option Exercise | 11,666 | — | 1/31/2025 |
| Watton Corey Michael | ▲ Buy | Open Market | 500 | $4K | 10/11/2024 |
| Clifton R. LaDuane | ▲ Buy | Open Market | 2,000 | $14K | 7/17/2024 |
| Anderson Thomas | ▲ Buy | Open Market | 10,000 | $68K | 7/16/2024 |
| John B. Bode | ▲ Buy | Open Market | 10,000 | $59K | 7/12/2024 |
| Clifton R. LaDuane | ▲ Buy | Open Market | 1,000 | $5K | 9/6/2023 |
| Anderson Thomas | ▲ Buy | Open Market | 10,000 | $49K | 9/6/2023 |
| Schafer Joshua | ▲ Buy | Open Market | 500 | $3K | 9/5/2023 |
| John B. Bode | ▲ Buy | Open Market | 10,000 | $51K | 9/5/2023 |
| Watton Corey Michael | ▲ Buy | Open Market | 275 | $2K | 6/23/2023 |
| Watton Corey Michael | ▲ Buy | Open Market | 325 | $2K | 6/9/2023 |
| Watton Corey Michael | ▲ Buy | Open Market | 400 | $2K | 5/30/2023 |
| Schafer Joshua | ▲ Buy | Open Market | 1,000 | $5K | 5/19/2023 |
| John B. Bode | ▲ Buy | Open Market | 1,390 | $7K | 5/18/2023 |
| John B. Bode | ▲ Buy | Open Market | 300 | $2K | 5/18/2023 |
| John B. Bode | ▲ Buy | Open Market | 1,000 | $5K | 5/18/2023 |
| John B. Bode | ▲ Buy | Open Market | 4,759 | $24K | 5/18/2023 |
| John B. Bode | ▲ Buy | Open Market | 100 | $505 | 5/18/2023 |
| John B. Bode | ▲ Buy | Open Market | 2,451 | $12K | 5/18/2023 |
| Clifton R. LaDuane | ▲ Buy | Open Market | 51 | $252 | 5/18/2023 |
| Clifton R. LaDuane | ▲ Buy | Open Market | 2,000 | $10K | 5/18/2023 |
| Clifton R. LaDuane | ▲ Buy | Open Market | 689 | $3K | 5/18/2023 |
| SEYMOUR TAMARA A | ▲ Buy | Open Market | 519 | $3K | 3/17/2023 |
| Schafer Joshua | ▲ Buy | Open Market | 2,000 | $9K | 3/14/2023 |
| Sangiovanni Timothy J. | ▲ Buy | Open Market | 1,100 | $5K | 3/10/2023 |
| Sangiovanni Timothy J. | ▲ Buy | Open Market | 100 | $414 | 3/10/2023 |
| Clifton R. LaDuane | ▲ Buy | Open Market | 1,725 | $7K | 3/10/2023 |
| Plooster Matthew R | ▲ Buy | Open Market | 11,000 | $46K | 3/9/2023 |
| Tierney David S | ▲ Buy | Open Market | 5,000 | $21K | 3/9/2023 |
| Pascoe Richard W | ▲ Buy | Open Market | 10,000 | $42K | 3/9/2023 |
| Clifton R. LaDuane | ▲ Buy | Open Market | 610 | $4K | 1/13/2023 |
| Clifton R. LaDuane | ▲ Buy | Open Market | 25 | $140 | 1/13/2023 |
| Pascoe Richard W | ▲ Buy | Open Market | 9,500 | $52K | 1/13/2023 |
| Clifton R. LaDuane | ▲ Buy | Open Market | 600 | $4K | 9/30/2022 |
| Clifton R. LaDuane | ▲ Buy | Open Market | 400 | $2K | 9/30/2022 |
| Tierney David S | ▲ Buy | Open Market | 2,000 | $9K | 5/25/2022 |
| Mickle Travis C | ▲ Buy | Open Market | 2,000 | $9K | 5/25/2022 |
| Mickle Travis C | ▲ Buy | Open Market | 1,000 | $4K | 5/25/2022 |
| Mickle Travis C | ▲ Buy | Open Market | 10,000 | $44K | 5/25/2022 |
| SEYMOUR TAMARA A | ▲ Buy | Open Market | 200 | $974 | 5/20/2022 |
| Plooster Matthew R | ▲ Buy | Open Market | 915 | $5K | 5/18/2022 |
| Plooster Matthew R | ▲ Buy | Open Market | 3,051 | $15K | 5/18/2022 |
| Plooster Matthew R | ▲ Buy | Open Market | 339 | $2K | 5/18/2022 |
| Pascoe Richard W | ▲ Buy | Open Market | 300 | $1K | 5/18/2022 |
| Pascoe Richard W | ▲ Buy | Open Market | 100 | $490 | 5/18/2022 |
| Pascoe Richard W | ▲ Buy | Open Market | 400 | $2K | 5/18/2022 |
| Pascoe Richard W | ▲ Buy | Open Market | 400 | $2K | 5/18/2022 |
| Pascoe Richard W | ▲ Buy | Open Market | 1,767 | $9K | 5/18/2022 |
| Pascoe Richard W | ▲ Buy | Open Market | 1,700 | $8K | 5/18/2022 |
| Pascoe Richard W | ▲ Buy | Open Market | 333 | $2K | 5/18/2022 |
| Clifton R. LaDuane | ▲ Buy | Open Market | 1,200 | $6K | 5/18/2022 |
| Plooster Matthew R | ▲ Buy | Open Market | 695 | $3K | 5/18/2022 |
| Plooster Matthew R | ▲ Buy | Grant | 2,500 | $21K | 12/1/2021 |
| Pascoe Richard W | ▲ Buy | Open Market | 1,500 | $12K | 11/30/2021 |
| Tierney David S | ▲ Buy | Open Market | 2,000 | $16K | 11/30/2021 |
| Mickle Travis C | ▲ Buy | Open Market | 2,250 | $19K | 11/18/2021 |
| Clifton R. LaDuane | ▲ Buy | Open Market | 510 | $4K | 11/18/2021 |
| Clifton R. LaDuane | ▲ Buy | Open Market | 215 | $2K | 9/29/2021 |
| Clifton R. LaDuane | ▲ Buy | Open Market | 935 | $8K | 9/20/2021 |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
Zevra Therapeutics Reports Cash Plus Deal Below Rival's Price
Zevra Therapeutics announced a cash-plus agreement for its drug, priced below the price offered by a rival company. The deal shows the company is willing to accept a lower price to secure a partnership. This could impact the company's valuation and competitive position in the market.
Zevra Therapeutics Reports Cash Plus Deal Below Rival's Price. Zevra Therapeutics announced a cash-plus agreement for its drug, priced below the price offered by a rival company. The deal shows the company is willing to accept a lower price to secure a partnership. This could impact the company's valuation and competitive position in the market.